US2013058972A1PendingUtilityA1

Methods for regulating complement cascade proteins using astrovirus coat protein and derivatives thereof

47
Individually held — no corporate assignee on recordPriority: Jun 15, 2006Filed: Jul 17, 2012Published: Mar 7, 2013
Est. expiryJun 15, 2026(expired)· nominal 20-yr term from priority
Inventors:Neel K. KrishnaKenji Cunnion
A61P 31/12A61P 9/10A61P 37/00A61P 7/06A61P 37/06A61P 43/00A61P 31/14A61P 25/00A61P 29/00A61P 25/28A61P 21/04C12N 2770/12033A61P 17/02C12N 2770/12032A61P 11/00A61P 13/12A61K 2039/5258A61P 19/04C12N 2770/12022A61K 38/00C07K 14/005A61P 19/02A61K 39/00
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a method for modulating the complement cascade by depleting the plasma of the functional activity of complement proteins and thereby reducing or eliminating complement-mediated cell lysis. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of viruses in the treatment of complement-mediated cell lysis and peptide mediators of inflammation. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of viruses in the treatment of complement-mediated diseases. Methods are described herein where complement cascade, triggered by either the classical or alternative complement pathways, is prevented from effecting cell lysis and inflammation due to inhibition or depletion of one or more complement components in the serum following administration of astrovirus coat proteins or derivatives.

Claims

exact text as granted — not AI-modified
1 . A method for inhibiting complement-mediated tissue damage comprising administering astrovirus coat protein or derivatives thereof. 
     
     
         2 . The method of  claim 1 , wherein the tissue damage is related to rheumatoid arthritis. 
     
     
         3 . The method of  claim 1 , wherein the tissue damage is related to systemic lupus erythematosus. 
     
     
         4 . The method of  claim 1 , wherein the tissue damage is related to multiple sclerosis. 
     
     
         5 . The method of  claim 1 , wherein the tissue damage is related to myasthenia gravis. 
     
     
         6 . The method of  claim 1 . wherein the tissue damage is related to autoimmune hemolytic anemia. 
     
     
         7 . The method of  claim 1 , wherein the tissue damage is related to membranoproliferative glomerulonephritis. 
     
     
         8 . The method of  claim 1 , wherein the tissue damage is related to serum sickness. 
     
     
         9 . The method of  claim 1 , wherein the tissue damage is related to turkey astrovirus infection. 
     
     
         10 . The method of  claim 1 , wherein the tissue damage is related to Adult Respiratory Distress Syndrome. 
     
     
         11 . The method of  claim 1 , wherein the tissue damage is related to ischemia reperfusion Injury 
     
     
         12 . The method of  claim 11 , wherein the ischemia-reperfusion injury results from stroke. 
     
     
         13 . The method of  claim 11 , wherein the ischemia-reperfusion injury results from myocardial infarction. 
     
     
         14 . The method of  claim 1 , wherein the tissue damage is related to allo- or xeno-transplantation. 
     
     
         15 . The method of  claim 14 , wherein the tissue injury is further the result of hyperacute rejection. 
     
     
         16 . The method of  claim 14 , wherein the tissue injury is further the result of graft versus host disease (GVHD). 
     
     
         17 . The method of  claim 1 , wherein the tissue damage is related to Alzheimer's Disease. 
     
     
         18 . The method of  claim 1 , wherein the tissue damage is related to burn injuries. 
     
     
         19 . The method of  claim 1 , wherein the tissue damage is related to hemodialysis damage. 
     
     
         20 . The method of  claim 1 , wherein the tissue damage is related to cardiopulmonary bypass damage. 
     
     
         21 . The method of  claim 1 , wherein the tissue damage is related to Paroxysmal Nocturnal Hemoglobinuria.

Join the waitlist — get patent alerts

Track US2013058972A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.